“Association between contemporary hormonal contraception and ovarian cancer… “ https://www.bmj.com/content/362/bmj.k3609 “Previous research has shown a reduced risk of ovarian cancer in users of combined oral contraceptives, an effect that persists for many years after stopping use. Changes have occurred in formulations of combined oral contraceptives (notably reductions in oestrogen dose and the introduction of newer progestogens). It is important for users of contemporary combined oral contraceptives to know whether they are likely to experience the same pattern of ovarian cancer benefit as users in the older studies. The Danish Sex Hormone Register Study follows a national cohort of women aged 15-79 years. It was established to investigate the relation between hormone use and the risk of cancer or cardiovascular disease. We calculated age standardised incidence rates of ovarian cancers per 100 000 person years, using the age distribution of the cohort as...

World Ovarian Coalition   This information comes from: -                  https://www.eurekalert.org/pub_releases/2018-10/wocc-doo101518.php "The World Ovarian Cancer Coalition Every Woman Study is the largest ever review of the experiences of women with ovarian cancer and includes contributions from the clinical community. It presents a bleak picture of the challenges faced by women with ovarian cancer, and those who care for them. Nine in ten of the women in the Every Woman Study experienced symptoms prior to diagnosis and of these, eight in ten consulted a doctor - though less than half within a month and one in ten waited six months. Across the world, diagnosis took an estimated average of 31 weeks from a woman experiencing symptoms to her diagnosis; for one in ten women diagnosis came more than a year after visiting a doctor. A survey participant in Australia said "Governments need to do more regarding G...

“Familial risks of ovarian cancer….” This information comes from:-        https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0205000 “Ovarian cancer risk increases with aging and peaks between the ages of 50 and 80 years. In the general Swedish population, the lifetime risk of ovarian cancer is 1%.  Family history is a strong risk factor for ovarian cancer, and the relative risk is estimated to be 2.0 to 4.0 for those that have a first-degree relative affected by the disease In this study, we use the recent national Swedish Family-Cancer Database, which included 16.1 million individuals, to estimate the familial risks of ovarian cancer by age at diagnosis, affected relative (mother or sisters) and histology. In families of only mother, only sisters or both mother and sisters diagnosed with ovarian cancer, cancer risks for ovary were 2.40, 2.59 and 10.40, respectively; and were higher for cases diagnosed before the age of...

This information comes from:- https://today.uic.edu/crosstalk-between-fallopian-tube-ovary-may-drive-the-spread-of-ovarian-cancer- - https://www.cancer.gov/news-events/cancer-currents-blog/2017/ovarian-cancer-fallopian-tube-origins "Over the last several years we have come to learn that ovarian cancer cells, specifically high-grade serous ovarian cancer cells, originate in the fallopian tube and migrate to the ovary where they become established as ovarian cancer.  We don’t know yet what the fallopian tube signals to the ovary, but we know that it causes the ovary to release norepinephrine, which signals cancer cells to migrate. - There is a window of several years between the development of abnormal cells, or lesions, in the fallopian tubes and the start of ovarian cancer Most of the genetic alterations seen in ovarian tumors in these patients were present in serous tubal intraepithelial carcinomas (STICs) that had formed years earlier in their fallopi...

"Poly (ADP-ribose) Polymerase Inhibitors (PARPi)  in the Management of Ovarian Cancer"   This information comes from https://www.ptcommunity.com/journal/article/full/2018/9/549/poly-adp-ribose-polymerase-inhibitors-management-ovarian-cancer-drug - https://www.eurekalert.org/pub_releases/2018-09/waeh-dpw092618.php "Familial and hereditary factors have been identified in the development of some cases of ovarian cancer, with approximately 10% to 15% of ovarian cancer cases associated with inherited mutations of the BRCA1 and BRCA2 genes. Upon recurrence of disease, the goal of treatment is no longer curative, but instead becomes palliative, aimed at improving disease-related symptoms, prolonging survival, and trying to improve quality of life. For patients harbouring a BRCA1/2 mutation, medications targeting PARP enzymes may be an effective therapeutic option. PARP is a family of enzymes that mediate DNA repair... PARP inhibition in the settin...

"FDA Funds Cosmetic Talc Study on Ovarian Cancer Risks" This information comes from:- https://www.drugjustice.com/news/talcum-powder/cosmetic-talc-study-ovarian-cancer/ "Cosmetic talc verdicts awarded billions to plaintiffs with ovarian cancer or mesothelioma over the past year. In all cases, the plaintiffs say regular talcum powder use (which contains cosmetic talc) led them to develop terminal cancer. However, some plaintiffs say asbestos (not cosmetic talc itself) may be the real culprit". "Scientists published the first study linking talcum powder to ovarian cancer in 1971( J Obstet Gynaecol Br Commonw. ). In the study, researchers dissected ovarian tumors and discovered talc particles embedded in 75% of them. Since then, dozens of different researchers validated that first study’s results. This includes a 2013 case-control study stating regular perineal talc use increased women’s ovarian cancer risk by 33%.( https://www.ncbi.nlm.nih.g...

"Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation"  This information is taken from:- bmj.k2644 This is a massive study looking at the cancer risk in all women in the UK who underwent fertility treatment during the period 1991-2010. The incidence of breast, uterine and ovarian cancer in treated women was compared with the normal. The conclusions were:- "No increased risk of corpus uteri or invasive breast cancer was detected in women who had had assisted reproduction, but increased risks of in situ breast cancer and invasive and borderline ovarian tumours were found in this study. Our results suggest that ovarian tumour risks could be due to patient characteristics, rather than assisted reproduction itself, although both surveillance bias and the effect of treatment are also possibilities. Ongoing m...